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in Patients With Acute Coronary Syndromes
To the Editor: Several studies have shown a clustering of recurrent
ischemic events shortly after discontinuation of heparin treatment
in patients with non–ST-segment elevation acute coronary syn-
drome (NSTE-ACS) (e.g., unstable angina and non–ST-segment
elevation myocardial infarction) (1,2). Uncontrolled thrombin
generation, partly facilitated through activated platelets, may be
an important trigger for recurrent ischemic events as suggested
by an increase in markers of thrombin activation within 24 h of
heparin discontinuation (3,4). Antiplatelet agents can partially
reduce such a prothrombotic tendency (1,2). The goal of this study
was to evaluate the effects of adding clopidogrel to aspirin on the
rebound increase of thrombin generation and activity after cessa-
tion of enoxaparin in NSTE-ACS patients.
The NSTE-ACS patients were eligible after stabilization by
standard treatment, which included aspirin (100 mg/day) and
enoxaparin (1 mg/kg twice daily subcutaneously). Patients were
randomly assigned to receive clopidogrel 300 mg followed by 75
mg/day in addition to aspirin (clopidogrel group), or no clopi-
dogrel (aspirin alone group). Glycoprotein IIb/IIIa inhibitors were
not used in any patient. Clopidogrel was started at the time of the
last enoxaparin administration and continued for at least 48 h. The
time point at 12 h after the last enoxaparin dose was considered as
the time of the loss of therapeutic enoxaparin levels and defined as
time  0. The study was approved by the institutional review
board. Blood samples were collected during enoxaparin treatment
just before the first clopidogrel dose, 12 h after the last enoxaparin
administration (time  0), and 3, 6, 12, 24, and 48 h thereafter.
The sampling frequency was based on previously published data
showing a rebound prothrombotic state approximately 5 to 10 h
after heparin discontinuation (3,4). Concentrations of prothrom-
bin fragment 1 and 2 (F12) and thrombin-antithrombin com-
plexes (TAT) were measured by sandwich-type enzyme-linked
immunosorbent assays (Dade-Behring, Marburg, Germany).
A sample size of 44 patients was estimated to have a 90% power
to detect a 50% reduction of the rebound in plasmatic TAT and
F12 levels. However, the introduction of clopidogrel as part of
the standard initial management of NSTE-ACS patients pre-
cluded the completion of the study (5). Within a treatment group,
the Wilcoxon test was performed to compare each of the eight
time points relative to time 0. For comparisons between the two
groups, the nonparametric Mann-Whitney test was used.
A total of 24 patients (12 per arm) were included. The
distribution of cardiovascular risk factors such as hypertension,
diabetes, dyslipidemia, body mass index, smoking, and a history of
cardiovascular events was comparable between the study groups.
All patients received at least three doses of enoxaparin, except
one patient in the clopidogrel group who received two doses. After
loss of therapeutic plasma enoxaparin levels, the aspirin alone
group showed a pronounced increase in TAT levels, with maxi-
mum levels at 12 and 24 h after cessation (Fig. 1). The TAT
concentrations at 6, 12, and 24 h were significantly higher than
baseline levels (Table 1). In contrast, TAT levels in the clopidogrel
group showed no increase at any time point after cessation of
enoxaparin, and remained similar to the baseline values. As
compared with the aspirin alone group, patients in the clopidogrel
group had a significantly lower increase in TAT levels from
baseline to 12 h (p 0.005). Both groups showed similar increases
of plasma F12 as soon as 3 h after cessation of heparin (Table 1).
The F12 levels at time points 3, 6, 12, and 24 h were significantly
higher in both groups compared with their baseline levels, and
maximum levels were reached at 24 h after cessation.
In conclusion, this study confirms that in ACS patients,
enoxaparin cessation results in a rapid increase of coagulation
activity as early as 3 h after loss of therapeutic anticoagulation
levels. This rebound state develops in spite of platelet inhibition by
aspirin, but can be partially inhibited by the addition of clopi-
dogrel. Patients on clopidogrel showed a less pronounced reacti-
vation in coagulation activity, as reflected by absent increases of
TAT complexes in contrast to the clear increase observed in
patients treated with aspirin alone. Recently, Eikelboom et al. (6)
found no differences in blood markers of coagulation activation
seven days after cessation of heparin therapy in patients with
NSTE-ACS treated with or without clopidogrel. However, this
study did not investigate variation in these markers in the first 24
to 48 h after heparin discontinuation, when the rebound phenom-
enon occurs (3,4). Among the several mechanisms that might
account for the rebound activation in coagulation after heparin
discontinuation are the depletion of natural anticoagulants such as
tissue factor pathway inhibitor or decreased activity in the protein
C pathway. In this context, thrombin generation after cessation of
heparin correlates inversely with tissue factor pathway inhibitor
concentrations (3), whereas data regarding the heparin effects on
the protein C pathway are discordant (7–9).
Figure 1. Median thrombin-antithrombin levels at different time points
during and after heparin treatment. Squares no clopidogrel; triangles
clopidogrel. Hour 0  12 h after last enoxaparin dose.
Journal of the American College of Cardiology Vol. 46, No. 8, 2005
© 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00
Published by Elsevier Inc.
In the current study, the thrombin generation marker F12 in
the clopidogrel group increased up to 24 h, whereas TAT, a
marker of thrombin activity, remained stable. An explanation
might be that clopidogrel could affect proteins that bind thrombin,
such as thrombomodulin or protease-activated receptors, thus
influencing the levels of circulating TAT.
In conclusion, rebound coagulation activity as reflected by
increasing thrombin generation occurs within hours after discon-
tinuation of low-molecular-weight heparin treatment. Clopidogrel
reduces this reactivation, and this might partially account for the
overall clinical benefits observed when adding clopidogrel to
aspirin treatment in ACS patients.
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Letters to the Editor
Pregnancy-Associated Plasma
Protein-A and Acute Coronary
Syndromes: Cause or Consequence?
Heeschen et al. (1) report an approximately two-fold risk of death
and myocardial infarction (MI) at 1 and 6 months linked with
pregnancy-associated plasma protein-A (PAPP-A) 12.6 mIU/l
among patients admitted for acute coronary syndromes (ACS),
even with normal troponin levels. The investigators hypothesize
plaque proteolysis by PAPP-A and harmful activation of insulin-
like growth factor-1 (IGF-1) through PAPP-A’s lysis of IGF-
binding proteins. We propose an alternative view.
Extracellular matrix degradation by PAPP-A, to our knowl-
edge, has never been documented. Moreover, IGF-1 exerts broad
cardiovascular protection, through insulin-sensitizing, nitric oxide–
mediated, antiapoptotic, regenerative, preconditioning, and anti-
inflammatory effects (2). How, then, can two apparently divergent
properties (predictor of risk for PAPP-A and vasculoprotective for
IGF-1) be reconciled?
Hypoxic/oxidative/inflammatory stress enhances PAPP-A’s
bioactivity (2–4). Circulating PAPP-A levels are increased in ACS
patients (1,4) and correlate (although not in all studies) with
indices of inflammation and myocardial damage (1,2,4). Experi-
mental damage raises local PAPP-A expression and IGF-1 bio-
activity (2,4) with immunomodulatory and anti-inflammatory
actions (4,5). During pregnancy, plasma PAPP-A is increased over
150-fold, with no parallel increase in ischemic risk; rather, reduced
PAPP-A predicts adverse outcomes (6). These data suggest that
PAPP-A is involved in physiological repair and replicative pro-
grams through its product, namely free IGF-1 (2–4).
Another circulating biomarker, B-type natriuretic peptide
(BNP), is cardioprotective and secreted in proportion to the extent
Table 1. Median Plasma Levels of Thrombin-Antithrombin Complex and of Prothrombin Fragment 12 in the Aspirin Plus
Clopidogrel and Aspirin-Alone Groups
Hours After Stopping
Enoxaparin
TAT (g/l) F12 (nmol/l)
12 0 3 6 12 24 48 12 0 3 6 12 24 48
Aspirin alone 4.6 4.1 6.8 6.7* 16.3† 17.0* 10.4 0.94 0.80 0.88* 0.97† 1.08† 1.14† 0.89
Aspirin plus clopidogrel 3.9 6.9 4.7 6.4 6.3 8.8 3.5 0.76 0.86 0.92* 0.98* 1.00* 1.34† 0.85
The p values are calculated in comparison to baseline (time 0) levels. Hour 0: 12 h after last enoxaparin dose. *p  0.05. †p  0.01.
F12  prothrombin fragment 12; TAT  thrombin-antithrombin complex.
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